AMTAGVI® (Lifileucel)

The FDA on February 16, 2024, granted accelerated approval to AMTAGVI®, a tumor-derived autologous T cell immunotherapy, for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor. AMTAGVI® is a product of Iovance Biotherapeutics, Inc.